Stock Alert: Immuron Surges Nearly 400%

Shares of Immuron Limited (IMRN) jumped nearly five-fold on Tuesday morning. The Australian biopharmaceutical company said that the US DoD Naval Medical Research Center requested a Pre-IND meeting with FDA on the development of a new oral therapeutic to prevent acute infectious diarrhea.

IMRN is currently trading at $10.60, up $8.40 or 381.82%, on the Nasdaq.

Immuron and the Naval Medical Research Center have currently teamed their research efforts to develop and clinically evaluate a new therapeutic against campylobacter and ETEC (E-Coli).

The NMRC recently requested a Pre-IND meeting with the FDA regarding its new investigational drug which the company is developing to treat moderate to severe campylobacteriosis and ETEC infections.

"We received a formal start work notification and approval at the end of January 2020 from the Henry Jackson Foundation for the Advancement of Military Medicine to commence work on the sub award," said Dr. Jerry Kanellos, CEO of Immuron Ltd.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Cryptocurrency Dogecoin's price jumped over 15% on Friday, but later lost some of the gains, after Tesla Inc. (TSLA) CEO Elon Musk announced that the luxury car maker will start accepting the meme cryptocurrency as payment for its merchandise. "Tesla merch buyable with Dogecoin," Musk tweeted on Friday. Dogecoin... US investment bank JPMorgan Chase & Co. reported Friday a profit for the fourth quarter that declined 14 percent from last year, hurt primarily by higher noninterest expense and lower credit reserve releases. Both adjusted earnings per share and revenues for the quarter topped analysts' expectations. Microsoft Corp. said its Board of Directors has initiated a review of the effectiveness of its workplace sexual harassment and gender discrimination policies and practices. The company has hired the law firm of Arent Fox to conduct the review mainly on sexual harassment investigations, including that of co-founder Bill Gates.
Follow RTT